Mezzion Pharma Co.,Ltd. (KOSDAQ: 140410)

Market Cap	925.87B
Revenue (ttm)	20.25B
Net Income (ttm)	-8.87B
Shares Out	29.96M
EPS (ttm)	-299.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	67,001
Open	30,850
Previous Close	30,900
Day's Range	30,050 - 31,550
52-Week Range	27,000 - 50,200
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About Mezzion Pharma Co.,Ltd.

Mezzion Pharma Co.,Ltd. engages in the development, manufacturing, and sale of pharmaceutical products in South Korea. It is developing udenafil, a PDE5 protein for the treatment of erectile dysfunction, benign prostatic hyperplasia, portal hypertension, pulmonary arterial hypertension, and single heart failure diseases. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 17
• Stock Exchange: KOSDAQ
• Ticker Symbol: 140410

Financial Performance

In 2023, Mezzion Pharma Co.,Ltd.'s revenue was 31.72 billion, an increase of 3.24% compared to the previous year's 30.73 billion. Losses were -12.73 billion, -64.93% less than in 2022.